#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
# Why This Matters for Clinicians and Patients
Clinicians need to understand that older adults represent a growing market segment for cannabis products and may be self-managing chronic conditions with high daily doses without medical supervision or monitoring. The lack of clinical guidance for older patients using substantial quantities of cannabis (40-50 mg daily) creates safety gaps around drug interactions, cognitive effects, and fall risk that physicians should actively address. Awareness of this trend enables clinicians to proactively screen for cannabis use in older patients and establish evidence-based dosing protocols rather than allowing patients to self-titrate potentially unsafe amounts.
This article examines the growing demographic of older adults obtaining medical cannabis cards and increasing their consumption patterns, noting that while this population represents a profitable market segment for dispensaries, it raises clinical concerns for healthcare providers. Older patients using cannabis at doses of 40-50 mg daily face particular risks including drug-drug interactions, cognitive effects, fall risk, and potential cardiovascular complications that are underappreciated in clinical settings. The disconnect between commercial incentives promoting higher consumption and medical evidence regarding safe dosing in geriatric populations highlights a gap in clinical oversight of cannabis use in older adults. Many physicians lack training to counsel elderly patients on appropriate cannabis dosing, potential adverse effects, and drug interactions relevant to their often complex medication regimens. Clinicians should proactively discuss cannabis use with older patients, establish baseline cognitive and functional status, and monitor for falls, medication interactions, and other age-related vulnerabilities when cannabis is used. For older patients considering or using cannabis, engagement with a knowledgeable healthcare provider to determine safe, effective dosing and monitor for adverse effects is essential to avoid harm.
“We’re seeing a significant shift in our older patient population turning to cannabis for chronic pain and sleep, which I understand given the opioid crisis, but the problem is most of them are self-titrating without any baseline data on their metabolism or drug interactions, and we simply don’t have the long-term safety studies in geriatric patients to guide dosing the way we do with conventional medications.”
🏥 The rising prevalence of cannabis use among older adults presents a meaningful clinical challenge that warrants attention in primary care and geriatric practice. While the increased use of cannabis by seniors may reflect both genuine therapeutic interest and changing social stigma around the drug, clinicians should recognize that older patients often have complex medication regimens, age-related changes in drug metabolism, and heightened vulnerability to cognitive and fall-related adverse effects that can complicate cannabis safety. The wide variability in dosing practices (as exemplified by daily intakes of 40-50 mg in some users) underscores the current absence of standardized, evidence-based dosing guidelines for older populations, making it difficult to counsel patients on safe thresholds. Providers should routinely ask older patients about cannabis use during medication reconciliation, document the frequency and form of consumption, and discuss potential interactions with their existing medications and conditions. Given the limited geriatric-specific safety
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: